|
Mon, 06/17/2024 - 12:04 |
Inhibikase Therapeutics Completes Enrollment of the Phase 2 201 Trial Evaluating Risvodetinib in Untreated Parkinsons Disease |
Inhibikase Ther... |
|
Wed, 05/15/2024 - 11:13 |
Inhibikase Therapeutics Announces Request for Withdrawal of S-1 Registration Statement |
Inhibikase Ther... |
|
Fri, 05/03/2024 - 21:33 |
New Evidence Explains Why Some Targeted Therapies Support Better Response to Cancer Immunotherapy |
Roswell Park Ca... |
|
Thu, 02/29/2024 - 03:52 |
Inhibikase Therapeutics Announces Full Outcomes of its Pre-NDA Meeting with the FDA for IkT-001Pro |
Inhibikase Ther... |
|
Wed, 02/07/2024 - 17:48 |
Inhibikase Therapeutics Announces Preliminary Outcomes of its Pre-NDA Meeting with the FDA on the Pathway for Approval for IkT-001Pro in Blood and Gastrointestinal Cancers |
Inhibikase Ther... |
|
Fri, 01/19/2024 - 13:52 |
Inhibikase Therapeutics Announces Planned Retirement of Chief Financial Officer Joseph Frattaroli |
Inhibikase Ther... |
|
Tue, 11/22/2022 - 08:57 |
Inhibikase Therapeutics to Present at Piper Sandler 34th Annual Healthcare Conference |
Inhibikase Ther... |
|
Tue, 08/23/2022 - 06:01 |
Inhibikase Therapeutics Announces Dosing of First Patient in its Phase 2a '201' Clinical Trial of IkT-148009 to Treat Parkinson's Disease |
Inhibikase Ther... |
|
Tue, 05/18/2021 - 01:24 |
Avapritinib Provided Greater Benefit Than Other Tyrosine Kinase Inhibitors for Mutated Gastrointestinal Stromal Tumors |
Fox Chase Cance... |
|
Tue, 12/08/2020 - 07:39 |
Asciminib Found Safe and Effective for Hard-to-Treat Chronic Myeloid Leukemia |
American Societ... |
|
Mon, 11/16/2020 - 03:07 |
Diamond helps in search for new breast cancer treatment |
Diamond Light Source |
|
Thu, 01/09/2020 - 14:47 |
Rigel to Present at the 38th Annual J.P. Morgan Healthcare Conference |
Rigel Pharmaceu... |
|
Wed, 01/08/2020 - 21:11 |
Blueprint Medicines Announces FDA Approval of AYVAKIT (avapritinib) for the Treatment of Adults with Unresectable or Metastatic PDGFRA Exon 18 Mutant Gastrointestinal Stromal Tumor |
Blueprint Medicines |
|
Fri, 01/03/2020 - 14:32 |
Fox Chase Team Awarded Grant to Research Rare GI Tumors |
Fox Chase |
|
Tue, 10/08/2019 - 23:43 |
Salk scientist Tony Hunter receives National Cancer Institute Outstanding Investigator Award |
Salk Institute |
|
Sat, 09/28/2019 - 08:02 |
Tolero Pharmaceuticals Presents Preliminary Findings from Phase 1 Study Evaluating Investigational Agent TP-0903 in Patients with Advanced Solid Tumors at ESMO 2019 |
SDP Oncology |
|
Thu, 06/27/2019 - 09:38 |
New Kinase Nomenclature Could Aid in Design of Cancer Drug Inhibitors |
Fox Chase Cance... |
|
Fri, 06/14/2019 - 13:10 |
Blueprint Medicines Submits New Drug Application to U.S. Food and Drug Administration for Avapritinib for the Treatment of PDGFRA Exon 18 Mutant GIST and Fourth-Line GIST |
Blueprint Medicines |
|
Thu, 05/30/2019 - 04:33 |
Tolero Pharmaceuticals Advances Investigational Agent TP-0903 into Phase 1b Expansion Stage of Study in Patients with Advanced Solid Tumors |
SDP Oncology |
|
Fri, 04/26/2019 - 08:43 |
'Lock-'n'-block' drug may prevent cancer from metastasizing |
Purdue |
|
Mon, 04/08/2019 - 01:59 |
JAPAN MHLW GRANTS SAKIGAKE DESIGNATION TO NOVEL FIBROBLAST GROWTH FACTOR (FGF) RECEPTOR SELECTIVE TYROSINE KINASE INHIBITOR E7090 |
EISAI |
|
Fri, 03/29/2019 - 09:15 |
Researchers discovered a new targetable vulnerability in breast cancer cells |
HelsinkiUniv |
|
Wed, 02/27/2019 - 09:34 |
Tolero Pharmaceuticals to Present New Data Evaluating Investigational Agents TP-0903 and TP-0184 at AACR Annual Meeting 2019 |
SDP Oncology |
|
Thu, 01/03/2019 - 10:56 |
Rigel to Present at the 37th Annual J.P. Morgan Healthcare Conference |
Rigel Pharmaceu... |
|
Thu, 11/15/2018 - 07:54 |
Tolero Pharmaceuticals Presents Clinical Data of AXL Kinase Inhibitor TP-0903 Showing its Ability to Enhance Host Immune Responses to Tumors |
SDP Oncology |
